Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer

Key Points

• Lutetium-177-PSMA-617 demonstrated comparable oncologic activity to phase 3 trials, suggesting effective treatment options exist for patients.
• In retrospective data, patients showed significant response to radioligand therapy with manageable outcomes over a shorter follow-up period.
• Analysis was based on real-world data collected from universal healthcare systems, indicating practical applicability of the findings in clinical settings.
• Study findings may support the integration of LUT-177-PSMA-617 in treatment protocols, but limitations due to short follow-up necessitate further research.